Veracyte Veracyte (formerly known as Calderome) is a genomic diagnostics company that specializes in molecular testing for the treatment of cancer. | ![]() SOPHiA GENETICS SOPHiA GENETICS is a healthcare technology company focused on establishing the practice of data-driven medicine. | Caris Life Sciences Caris Life Sciences is a molecular science company that provides cancer care services. | ![]() Castle Biosciences Castle Biosciences is a company developing and commercializing diagnostic and prognostic tests for dermatologic cancers. | ![]() Roka Bioscience Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. | ID Genomics ID Genomics is a company offering microbial identification, typing, and genomic analysis services. | ![]() MDxHealth MDxHealth is a molecular diagnostics company that develops and commercializes tests for cancer and other urologic diseases diagnosis. | ![]() Curetis Curetis is a molecular diagnostic firm focused on the development and commercialization of tools for diagnosing severe infectious diseases. | ||||
Founding Date | Founding Date 2008 | Founding Date 2011 | Founding Date 2011 | Founding Date 2008 | Founding Date 2008 | Founding Date 2005 | Founding Date 2009 | Founding Date 2003 | Founding Date 2012 | Founding Date 2003 | Founding Date 2007 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Private | Type Private | Type Private | Type Public | Type Subsidiary |
Tags | |||||||||||
Locations | Locations South San Francisco, US HQ Marseille, FR Haifa, IL Austin, US San Diego, US | Locations Fremont, US HQ West Wickham, GB | Locations Rolle, CH HQ Bidart, FR Boston, US | Locations Friendswood, US HQ Phoenix, US | Locations Boulder, US HQ De Soto, US | Locations Warren, US HQ | Locations Redwood City, US HQ Greensboro, US | Locations Seattle, US HQ Seattle, US | Locations Herstal, BE HQ Nijmegen, NL Irvine, US Plano, US | Locations Holzgerlingen, DE HQ | |
Employees | Employees 8154% increase | Employees 22344% decrease | Employees 423 | Employees 1,468 | Employees 61013% increase | Employees 21711% decrease | Employees 225% increase | Employees 609% decrease | Employees 2 | Employees 252 | Employees 57 |
Valuation ($) | Valuation ($) 2.6 b | Valuation ($) 340.9 m | Valuation ($) 236.4 m | Valuation ($) N/A | Valuation ($) 936.9 m | Valuation ($) 239.5 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 93.5 m | Valuation ($) N/A |
Financial | |||||||||||
Revenue (est.) | Revenue (est.) $517.1m (FY, 2025) | Revenue (est.) $69.6m (FY, 2025) | Revenue (est.) $65.2m (FY, 2024) | Revenue (est.) $812m (FY, 2025) | Revenue (est.) $344.2m (FY, 2025) | Revenue (est.) $88.5m (FY, 2025) | Revenue (est.) $7.2m (FY, 2016) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $107.9m (FY, 2025) | Revenue (est.) €1.4m (FY, 2018) |
Cost of goods | Cost of goods N/A | Cost of goods $53.9m (FY, 2025) | Cost of goods $17.7m (FY, 2024) | Cost of goods N/A | Cost of goods $71m (FY, 2025) | Cost of goods N/A | Cost of goods $8m (FY, 2016) | Cost of goods N/A | Cost of goods N/A | Cost of goods $36.1m (FY, 2025) | Cost of goods €2m (FY, 2018) |
Gross profit | Gross profit $362.5m (FY, 2025) | Gross profit $15.8m (FY, 2025) | Gross profit $47.6m (FY, 2024) | Gross profit N/A | Gross profit $273.2m (FY, 2025) | Gross profit N/A | Gross profit ($732k) (FY, 2016) | Gross profit N/A | Gross profit N/A | Gross profit $71.8m (FY, 2025) | Gross profit €138k (FY, 2018) |
Net income | Net income $66.4m (FY, 2025) | Net income ($81.3m) (FY, 2025) | Net income ($62.5m) (FY, 2024) | Net income ($68.1m) (FY, 2025) | Net income ($24.2m) (FY, 2025) | Net income ($35.3m) (FY, 2025) | Net income ($30.8m) (FY, 2016) | Net income N/A | Net income N/A | Net income ($33.5m) (FY, 2025) | Net income (€23.7m) (FY, 2018) |
Operating ⚠ | |||||||||||
Completed Clinical Studies to Date | Completed Clinical Studies to Date 50 (FY, 2020) | Completed Clinical Studies to Date N/A | Completed Clinical Studies to Date N/A | Completed Clinical Studies to Date N/A | Completed Clinical Studies to Date N/A | Completed Clinical Studies to Date 23 (Q2, 2020) | Completed Clinical Studies to Date N/A | Completed Clinical Studies to Date N/A | Completed Clinical Studies to Date N/A | Completed Clinical Studies to Date N/A | Completed Clinical Studies to Date N/A |
Customers | Customers N/A | Customers N/A | Customers 382 (FY, 2021) | Customers N/A | Customers N/A | Customers N/A | Customers N/A | Customers N/A | Customers N/A | Customers 1 k (FY, 2021) | Customers N/A |
Facility Space Leased, sq. ft. | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. 42.6 k (FY, 2021) | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. 61.5 k (FY, 2021) | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A |
Patents (US) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) 12 (Q1, 2022) | Patents (US) N/A | Patents (US) N/A | Patents (US) 3 (Sep, 2022) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A |
Patents Issued | Patents Issued N/A | Patents Issued 16 (FY, 2021) | Patents Issued N/A | Patents Issued N/A | Patents Issued 72 (FY, 2021) | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A |
Peer-Reviewed Publications Published | Peer-Reviewed Publications Published N/A | Peer-Reviewed Publications Published N/A | Peer-Reviewed Publications Published 330 (FY, 2021) | Peer-Reviewed Publications Published N/A | Peer-Reviewed Publications Published N/A | Peer-Reviewed Publications Published 275 (Q2, 2020) | Peer-Reviewed Publications Published N/A | Peer-Reviewed Publications Published N/A | Peer-Reviewed Publications Published N/A | Peer-Reviewed Publications Published N/A | Peer-Reviewed Publications Published N/A |
Trademarks (US) | Trademarks (US) N/A | Trademarks (US) N/A | Trademarks (US) 9 (FY, 2021) | Trademarks (US) N/A | Trademarks (US) 13 (FY, 2021) | Trademarks (US) N/A | Trademarks (US) N/A | Trademarks (US) N/A | Trademarks (US) N/A | Trademarks (US) N/A | Trademarks (US) N/A |
Funding | |||||||||||
Latest funding round | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 17m (over 12 years ago) | Latest funding round $ 22.5m (over 9 years ago) | Latest funding round $ 3m (about 10 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 116.3m | Total funding raised $ 75m | Total funding raised $ 245.8m | Total funding raised $ 1.1b | Total funding raised $ 46.5m | Total funding raised $ 98.2m | Total funding raised $ 109.5m | Total funding raised $ 311.3m | Total funding raised $ 3m | Total funding raised $ 1.1m | Total funding raised $ 67.8m |

Personalis is a biotechnology company that specializes in cancer genomics.
View company
SOPHiA GENETICS is a healthcare technology company focused on establishing the practice of data-driven medicine.
View companyCaris Life Sciences is a molecular science company that provides cancer care services.
View company
Castle Biosciences is a company developing and commercializing diagnostic and prognostic tests for dermatologic cancers.
View company